Seraph 100 May Reduce Tumor Particles in Blood Samples from Pancreatic Cancer Patients A recent laboratory study has explored the potential therapeutic benefits of blood purification for patients with metastatic pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and…
Bruker Enhances Single-Cell Proteomics and Immunopeptidomics with New Software at US HUPO At the 21st Annual US HUPO Conference, Bruker Corporation (Nasdaq: BRKR) unveiled significant advancements in 4D-Proteomics™ performance, along with new software and applications aimed at providing deeper biological…
FDA Accepts Bristol Myers Squibb’s Application for Opdivo® + Yervoy® in MSI-High or MMR-Deficient Cancer Bristol Myers Squibb (NYSE: BMY) recently announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental biologics license application (sBLA) for Opdivo®…
Summit Therapeutics Reports Q4 and 2024 Full-Year Financial and Operational Results Summit Therapeutics Inc. (NASDAQ: SMMT) has provided an update on its operational progress and financial results for the fourth quarter and full year ending December 31, 2024. The company…
Almirall 2024 Results: Surpasses Guidance, Poised for Sustained Growth Almirall, S.A., a global biopharmaceutical company based in Barcelona, has reported strong financial results for the full year of 2024. The company saw a notable increase in total revenue, achieving €990.6…
Samsung Bioepis Launches PYZCHIVA® (Biosimilar to Stelara) in the US Samsung Bioepis Co., Ltd. has announced the U.S. launch of PYZCHIVA® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab). PYZCHIVA is approved for treating moderate to severe plaque psoriasis in patients eligible…
Elevance Health Reports Q4 and Full Year 2024 Results, 2025 Outlook Elevance Health, Inc. (NYSE: ELV) reported strong results for the fourth quarter and full year of 2024, showcasing continued growth and operational improvements despite the challenges facing the healthcare…
Triastek’s D23 (Budesonide Ileum-Targeted Tablet) Shows Positive Clinical Results Triastek has announced that its 3D-printed drug, D23 (Budesonide Ileum-Targeted Tablet), has achieved positive results in a recent clinical trial aimed at treating IgA nephropathy (IgAN). D23 is a budesonide delayed-release…
Celltrion Gets EC Approval for Avtozma® (CT-P47), Biosimilar to RoActemra® Celltrion announced today that it has received marketing authorization from the European Commission (EC) for Avtozma® (CT-P47), a biosimilar referencing the reference biologic RoActemra® (tocilizumab). This approval allows Avtozma® to…
Hartford HealthCare Partners with K Health to Transform Primary Care Hartford HealthCare has partnered with K Health to revolutionize primary care delivery in Connecticut. The collaboration aims to redefine access to primary care using advanced clinical AI. As one of…
KalVista to Present New Sebetralstat Data at AAAAI 2025 Annual Meeting KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) has announced that six of its abstracts have been accepted for presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World…
Iterative Health to Showcase AI Advancements at ECCO 2025 for Ulcerative Colitis Trials Iterative Health, a healthcare technology and services company focused on advancing gastrointestinal care in partnership with physicians, will present five abstracts at the European Crohn’s & Colitis…